IPP Bureau
Roche provides update on astegolimab in chronic obstructive pulmonary disease
By IPP Bureau - July 21, 2025
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Sun Pharma’s phase 3 Cclinical studies for Tildrakizumab 100 mg meet primary endpoint
By IPP Bureau - July 21, 2025
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
By IPP Bureau - July 21, 2025
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
AstraZeneca’s Tagrisso plus chemotherapy improves overall survival in EGFR-mutated advanced lung cancer
By IPP Bureau - July 21, 2025
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
ImCheck’s ICT01 receives FDA ODD for treatment of acute myeloid leukemia
By IPP Bureau - July 21, 2025
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Neuberg Pulse partners with Dhoni to launch diagnostics centre in Ranchi
By IPP Bureau - July 21, 2025
Neuberg group commits to invest over Rs. 100 crores to start diagnostics facilities across Jharkhand in the next 2-3 years
Bayer’s Nubeqa receives EU approval for patients with advanced prostate cancer
By IPP Bureau - July 21, 2025
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Biogen to invest $2 billion to expand manufacturing capability in North Carolina
By IPP Bureau - July 21, 2025
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl
By IPP Bureau - July 19, 2025
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Vimta Labs Q1 FY26 PAT climbs to Rs. 18.89 Cr
By IPP Bureau - July 18, 2025
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
Zigly launches its first pet hospital in Mumbai
By IPP Bureau - July 18, 2025
The new Zigly center features and offers comprehensive veterinary services
Kenvue collaborates with API to launch India’s first cough clinics
By IPP Bureau - July 18, 2025
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Brenntag Specialties Pharma offering phosphate-based excipients by Budenheim
By IPP Bureau - July 18, 2025
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2
By IPP Bureau - July 18, 2025
The company is addressing these observations comprehensively
